Echo Therapeutics (ECTE) Stock Price, News & Analysis

Company Overview

Echo Therapeutics, Inc. is a medical device company historically focused on developing noninvasive and continuous glucose-monitoring technologies. Its work centered on methods for measuring glucose through the skin, with the goal of providing an alternative to conventional blood sampling.

The company’s principal product platform was the Symphony transdermal continuous glucose-monitoring system. Symphony was designed to use a sensor placed on prepared skin to monitor glucose levels continuously and transmit readings wirelessly to a monitor or receiver. Echo Therapeutics also developed the Prelude skin-preparation system, intended to remove the outermost layer of skin and improve contact between the skin and the glucose sensor.

Echo Therapeutics pursued development and clinical evaluation of these technologies for use in hospital and other clinical settings, including monitoring patients who required frequent glucose measurements. Publicly available information about the company’s current operations, commercial product availability, geographic presence and leadership is limited.

Key Stats

• Today's Range: $0.0002 to $0.0002
• 50-Day Range: N/A
• 52-Week Range: $0.00 to $0.28
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Last Earnings: 8/12/2016
• Today: 10/16/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: OTCMKTS:ECTE
• Previous Symbol: NASDAQ:ECTE
• CIK: 1031927
• Web: www.echotx.com
• Phone: (732) 201-4194
• Fax: 215-717-4109
• Employees: 19
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A